# Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

> **NCT03437785** · PHASE2 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 250 (actual)

## Conditions studied

- Gastritis

## Interventions

- **DRUG:** CKD-495 75mg
- **DRUG:** CKD-495 150mg
- **DRUG:** Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg
- **DRUG:** Rebamipide 100mg
- **DRUG:** Placebo of the CKD-495 75mg
- **DRUG:** Placebo of the CKD-495 150mg
- **DRUG:** Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
- **DRUG:** Placebo of the Rebamipide 100mg

## Key facts

- **NCT ID:** NCT03437785
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-16
- **Primary completion:** 2018-10-12
- **Final completion:** 2018-10-12
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03437785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03437785, "Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03437785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*